Apoptosis in the development and treatment of cancer

Carcinogenesis

Volumn 26, Issue 2, 2005, Pages 263-270

  Gerl, Robert ^a   Vaux, David L ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; DEATH RECEPTOR; DEXAMETHASONE; GEFITINIB; IMATINIB; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN ANTAGONIST; LIGAND; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL 2 ANTAGONIST; PROTEIN P53; PROTEIN P53 PROTEIN MDMX2 COMPLEX; RITUXIMAB; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; STEROID; SURVIVIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; CYTOTOXICITY; ENZYME ACTIVATION; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT GENE; LUNG CANCER; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STRESS; TRANSGENICS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; GENES, P53; HUMANS; MICE; MITOSIS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 13844280932     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh283     Document Type: Article

References (108)

1. Kerr,J.F., Wyllie,A.H. and Currie,A.R. (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 26, 239-257.
2. Searle,J., Lawson,T.A., Abbott,P.J., Harmon,B. and Kerr,J.F. (1975) An electron-microscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J. Pathol., 116, 129-138.
3. Vaux,D.L., Cory,S. and Adams,J.M. (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature, 335, 440-442.
4. Strasser,A., Harris,A.W. and Cory,S. (1991) bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell, 67, 889-999.
5. Tsujimoto,Y. (1989) Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. Oncogene, 4, 1331-1336.
6. Strasser,A., Harris,A.W., Bath,M.L. and Cory,S. (1990) Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature, 348, 331-333.
7. Ekert,P.G., Read,S.H., Silke,J., Marsden,V.S., Kaufmann,H., Hawkins,C.J., Gerl,R., Kumar,S. and Vaux,D.L. (2004) Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J. Cell Biol., 165, 835-842.
8. Tannock,I.F. and Lee,C. (2001) Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs. Br. J. Cancer, 84, 100-105.
9. Vaux,D.L. (2002) Apoptosis and toxicology - what relevance? Toxicology, 181/182, 3-7.
10. Evan,G.I., Wyllie,A.H., Gilbert,C.S., Littlewood,T.D., Land,H., Brooks,M., Waters,C.M., Penn,L.Z. and Hancock,D.C. (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69 119-128.
11. Askew,D.S., Ashmun,R.A., Simmons,B.C. and Cleveland,J.L. (1991) Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6, 1915-1922.
12. Pelengaris,S., Khan,M. and Evan,G.I. (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell, 109, 321-334.
13. Yuan,J.Y., Shaham,S., Ledoux,S., Ellis,H.M. and Horvitz,H.R. (1993) The C.elegans cell death gene ced 3 encodes a protein similar to mammalian interleukin 1 beta converting enzyme. Cell, 75, 641-652.
14. Ellis,H.M. and Horvitz,H.R. (1986) Genetic control of programmed cell death in the nematode C.elegans. Cell, 44, 817-829.
15. Nicholson,D.W. and Thornberry,N.A. (1997) Caspases - killer proteases. Trends Biochem. Sci., 22, 299-306.
16. Cohen,G.M. (1997) Caspases - the executioners of apoptosis. Biochem. J., 326, 1-16.
17. Liu,X.S., Kim,C.N., Yang,J., Jemmerson,R. and Wang,X.D. (1996) Induction of apoptotic program in cell-free extracts - requirement for datp and cytochrome c. Cell, 86, 147-157.
18. Desagher,S. and Martinou,J.C. (2000) Mitochondria as the central control point of apoptosis. Trends Cell Biol., 10, 369-377.
19. Wu,D.Y., Wallen,H.D., Inohara,N. and Nunez,G. (1997) Interaction and regulation of the Caenorhabditis elegans death protease ced-3 by ced-4 and ced-9. J. Biol. Chem., 272, 21449-21454.
20. Spector,M.S., Desnoyers,S., Hoeppner,D.J. and Hengartner,M.O. (1997) Interaction between the c-elegans cell-death regulators ced-9 and ced-4. Nature, 385, 653-656.
21. Wu,D.Y., Wallen,H.D. and Nunez,G. (1997) Interaction and regulation of subcellular localization of ced-4 by ced-9. Science, 275, 1126-1129.
22. Li,P., Nijhawan,D., Budihardjo,I., Srinivasula,S.M., Ahmad,M., Alnemri,E.S. and Wang,X.D. (1997) Cytochrome c and datp-dependent formation of apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91, 479-489.
23. Shi,Y.G. (2002) Apoptosome: the cellular engine for the activation of caspase-9. Structure, 10, 285-288.
24. Enari,M., Sakahira,H., Yokoyama,H., Okawa,K., Iwamatsu,A. and Nagata,S. (1998) A caspase-activated dnase that degrades dna during apoptosis and its inhibitor ICAD. Nature, 391, 43-50.
25. Hewish,D.R. and Burgoyne,L.A. (1973) Chromatin sub-structure. The digestion of chromatin DNA at regularly spaced sites by a nuclear deoxyribonuclease. Biochem. Biophys. Res. Commun., 52, 504-510.
26. Williams,J.R., Little,J.B. and Shipley,W.U. (1974) Association of mammalian cell death with a specific endonucleolytic degradation of DNA. Nature, 252, 754-755.
27. Honarpour,N., Du,C.Y., Richardson,J.A., Hammer,R.E., Wang.X.D. and Herz,J. (2000) Adult Apaf-1-deficient mice exhibit male infertility. Dev. Biol., 218, 248-258.
28. Zheng,T.S. and Flavell,R.A. (2000) Divinations and surprises: genetic analysis of caspase function in mice. Exp. Ceil Res., 256, 67-73.
29. Leonard,J.R., Klocke,B.J., D'Sa,C., Flavell,R.A. and Roth,K.A. (2002) Strain-dependent neurodevelopmental abnormalities in caspase-3-deficient mice. J. Neuropathol. Exp. Neurol., 61, 673-677.
30. Ho,A.T., Li,Q.H., Hakem,R., Mak,T.W. and Zacksenhaus.E. (2004) Coupling of caspase-9 to Apaf1 in response to loss of pRb or cytotoxic drugs is cell-type-specific. EMBO J., 23, 460-472.
31. Ashkenazi,A. and Dixit,V.M. (1999) Apoptosis control by death and decay receptors. Curr. Opin. Cell, Biol., 11, 255-260.
32. Strasser,A., O'Connor,L. and Dixit,V.M. (2000) Apoptosis signaling. Annu. Rev. Biochem., 69, 217-245.
33. Tewari,M. and Dixit,V.M. (1995) Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crma gene product. J. Biol. Chem., 270, 3255-3260.
34. Strasser,A., Harris,A.W., Huang,D.C.S., Krammer,P.H. and Cory,S. (1995) Bcl-2 and fas/apo-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J., 14, 6136-6147.
35. Moriishi,K., Huang,D.C.S., Cory,S. and Adams,J.M. (1999) Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. Proc. Natl Acad. Sci. USA, 96, 9683-9688.
36. Adams,J.M. (2003) Ways of dying: multiple pathways to apoptosis. Genes Dev., 17, 2481-2495.
37. Lindsten,T., Ross,A.J., King,A. et al. (2000) The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol. Cell, 6, 1389-1399.
38. Wei,M.C., Zong,W.X., Cheng,E.H.Y. et al. (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science, 292, 727-730.
39. Bouillet,P. and Strasser,A. (2002) BH3-only proteins - evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. J. Cell Sci., 115, 1567-1574.
40. Chen,F.L., Hersh,B.M., Conradt,B., Zhou,Z., Riemer,D., Gruenbaum,Y. and Horvitz,H.R. (2000) Translocation of C.elegans CED-4 to nuclear membranes during programmed cell death. Science, 287, 1485-1489.
41. Nakano,K. and Vousden,K.H. (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell, 7, 683-694.
42. Villunger,A., Michalak,E.M., Coultas,L., Mullauer,F., Bock,G., Ausserlechner,M,J., Adams,J.M. and Strasser,A. (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science, 302, 1036-1038.
43. Puthalakath,H., Huang,D.C.S., O'Reilly,L.A., King,S.M. and Strasser,A. (1999) The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell, 3, 287-296.
44. Puthalakath,H., Villunger,A., O'Reilly,L.A., Beaumont,J.G., Coultas,L., Cheney,R.E., Huang,D.C.S. and Strasser,A. (2001) Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science, 293, 1829-1832.
45. Li,H.L., Zhu,H., Xu,C.J. and Yuan,J.Y. (1998) Cleavage of bid by caspase 8 mediates the mitochondrial damage in the fas pathway of apoptosis. Cell, 94, 491-501.
46. Zha,J.P., Harada,H., Yang,E., Jockel,J. and Korsmeyer,S.J. (1996) Serine phosphorylation of death agonist bad in response to survival factor results in binding to 14-3-3 not bgl-x(l). Cell, 87, 619-628.
47. Salvesen,G.S. and Duckett,C.S. (2002) IAP proteins: blocking the road to death's door. Nature Rev. Mol. Cell Biol., 3, 401-410.
48. Shi,Y.G. (2002) Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell, 9, 459-470.
49. Yoo,S.J., Huh,J.R., Muro,I. et al. (2002) Hid, Rpr and Grim negatively regulate DIAP1 levels through distinct mechanisms. Nature Cell Biol., 4, 416-424.
50. Zachariou,A., Tenev,T,, Goyal,L., Agapite,J., Steller,H. and Meier,P. (2003) IAP-antagonists exhibit non-redundant modes of action through differential DIAP1 binding. EMBO J., 22, 6642-6652.
51. Vaux,D.L. and Silke,J. (2003) Mammalian mitochondrial IAP binding proteins. Biochem. Biophys. Res. Commun., 304, 499-504.
52. Strasser,A., Harris,A.W. and Cory,S. (1993) E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene, 8, 1-9.
53. McDonnell,T.J. and Korsmeyer,S.J. (1991) Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature, 349, 254-256.
54. Egle,A., Harris,A.W., Bath,M.L., O'Reilly,L. and Cory,S. (2004) VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood, 103, 2276-2283.
55. Donehower,L.A., Harvey,M., Slagle,B.L., McArthur,M.J., Montgomery,C.J., Butel,J.S. and Bradley,A. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.
56. Lane,D.P. (1992) Cancer. p53, guardian of the genome. Nature, 358, 15-16.
57. el-Deiry,W.S., Tokino,T., Velculescu,V.E. et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75 817-825.
58. Yu,J., Zhang,L., Hwang,P.M., Kinzler,K.W. and Vogelstein,B. (2001) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell, 7, 673-682.
59. Strasser,A., Harris,A.W., Jacks,T. and Cory,S. (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell, 79, 329-339.
60. Deng,C.X., Zhang,P.M., Harper,J.W., Elledge,S.J. and Leder,P. (1995) Mice lacking p21(c/p1/waf1) undergo normal development, but are defective in g1 checkpoint control. Cell, 82, 675-684.
61. Mihara,M., Erster,S., Zaika,A., Petrenko,O., Chittenden,T., Pancoska,P. and Moll,U.M. (2003) p53 has a direct apoptogenic role at the mitochondria. Mol. Cell, 11, 577-590.
62. Schmitt,C.A., Fridman,J.S., Yang,M., Baranov,E., Hoffman,R.M. and Lowe,S.W. (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell, 1, 289-298.
63. Suzuki,H., Motegi,M., Akagi,T., Hosokawa,Y. and Seto,M. (1999) API1-MALT1/MLT is involved in mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21). Blood, 94, 3270-3271.
64. Morgan,J.A., Yin,Y., Borowsky,A.D. et al. (1999) Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res., 59, 6205-6213.
65. Dierlamm,J., Baens,M., Wlodarska,I. et al. (1999) The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood, 93, 3601-3609.
66. Uren,A.G., O'Rourke,K., Aravind,L., Pisabarro,M.T., Seshagiri,S., Koonin,E.V. and Dixit,V.M. (2000) Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol. Cell 6, 961-967.
67. Lucas,P.C., Yonezumi,M., Inohara,N., McAllister-Lucas,L.M., Abazeed,M.E., Chen,F.F., Yamaoka,S., Seto,M. and Nunez,G. (2001) Bcl10 and MALT1, independent targets of chromosomal translocation in MALT lymphoma, cooperate in a novel NF-kappa B signaling pathway. J. Biol. Chem., 276, 19012-19019.
68. Willis,T.G., Jadayel,D.M., Du,M.Q. et al. (1999) Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell, 96, 35-45.
69. Leiter,U., Schmid,R.M., Kaskel,P., Peter,R.U. and Krahn,G. (2000) Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch. Dermatol. Res., 292, 225-232.
70. Pettersson,M., Jernberg-Wiklund,H., Larsson,L.G., Sundstrom,C., Givol,I., Tsujimoto,Y. and Nilsson,K. (1992) Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood, 79, 495-502.
71. Jourdan,M., Veyrune,J.L., Vos,J.D., Redal,N., Couderc,G. and Klein,B. (2003) A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene, 22, 2950-2959.
72. Ekedahl,J., Joseph,B., Grigoriev,M.Y., Muller,M., Magnusson,C., Lewensohn,R. and Zhivotovsky,B. (2002) Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp. Cell Res., 279, 277-290.
73. Hofmann,H.S., Simm,A., Hammer,A., Silber,R.E. and Bartling,B. (2002) Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J. Cancer Res. Clin. Oncol., 128, 554-560.
74. Chiodino,C., Cesinaro,A.M., Ottani,D., Fantini,F., Giannetti,A., Trentini,G.P. and Pincelli,C. (1999) Expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J. Invest. Dermatol., 113, 415-418.
75. Vucic,D., Stennicke,H.R., Pisabarro,M.T., Salvesen,G.S. and Dixit,V.M. (2000) ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol., 10, 1359-1366.
76. Kasof,G.M. and Gomes,B.C. (2001) Livin, a novel inhibitor of apoptosis protein family member. J. Biol. Chem., 276, 3238-3246.
77. Skoufias,D.A., Mollinari,C., Lacroix,F.B. and Margolis,R.L. (2000) Human survivin is a kinetochore-associated passenger protein. J. Cell Biol., 151, 1575-1581.
78. Uren,A.G., Wong,L., Pakusch,M., Fowler,K.J., Burrows,F.J., Vaux,D.L. and Choo,K.H.A. (2000) Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol., 10, 1319-1328.
79. Silke,J. and Vaux,D.L. (2001) Two kinds of BIR-containing protein-inhibitors of apoptosis, or required for mitosis. J. Cell Sci. 114, 1821-1827.
80. Carvalho,A., Carmena,M., Sambade,C., Earnshaw,W.C. and Wheatley,S.P. (2003) Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J. Cell Sci., 116, 2987-2998.
81. Egle,A., Harris,A.W., Bouillet,P. and Cory,S. (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl Acad. Sci. USA, 12, 12.
82. Eischen,C.M., Roussel,M.F., Korsmeyer,S.J. and Cleveland,J.L. (2001) Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol., 21, 7653-7662.
83. Swanson,P.J., Kuslak,S.L., Fang,W. et al. (2004) Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc. J. Immunol., 172, 6684-6691.
84. Hemann,M.T., Zilfou,J.T., Zhao,Z., Burgess,D.J., Hannon,G.J. and Lowe,S.W. (2004) Suppression of tumorigenesis by the p53 target PUMA. Proc. Natl Acad. Sci. USA, 101, 9333-9338.
85. Zhou,P., Levy,N.B., Xie,H., Qian,L., Lee,C.Y., Gascoyne,R.D. and Craig,R.W. (2001) MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 97, 3902-3909.
86. Scott,C.L., Schuler,M., Marsden,V.S. et al. (2004) Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation. J. Cell Biol., 164, 89-96.
87. Allen,S.M., Florell,S.R., Hanks,A.N., Alexander,A., Diedrich,M.J., Altieri,D.C. and Grossman,D. (2003) Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res., 63, 567-572.
88. Brown,J.M. and Wouters,B.G. (1999) Apoptosis, p53 and tumor cell sensitivity to anticancer agents. Cancer Res., 59, 1391-1399.
89. Kaufmann,S.H. and Hengartner,M.O. (2001) Programmed cell death: alive and well in the new millennium. Trends Cell Biol., 11, 526-534.
90. Kaufmann,S.H. and Vaux,D.L. (2003) Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene, 22, 7414-7430.
91. Sentman,C.L., Shutter,J.R., Hockenbery,D., Kanagawa,O. and Korsmeyer,S.J. (1991) bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell, 67, 879-888.
92. Liu,X., Chua,C.C., Gao,J., Chen,Z., Landy,C.L., Hamdy,R. and Chua,B.H. (2004) Pifithrin- {alpha} protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice. Am. J. Physiol. Heart Circ. Physiol., 286, H933-H939.
93. Komarov,P.G., Komarova,E.A., Kondratov,R.V., Christov-Tselkov,K., Coon,J.S., Chemov,M.V. and Gudkov,A.V. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science, 285, 1733-1737.
94. Stoelcker,B., Ruhland,B., Hehlgans,T., Bluethmann,H., Luther,T. and Mannel,D.N. (2000) Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am. J. Pathol., 156, 1171-1176.
95. LeBlanc,H.N. and Ashkenazi,A. (2003) Apo2L/TRAIL and its death and decay receptors. Cell Death Differ., 10, 66-75.
96. Frankel,S.R. (2003) Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Semin. Oncol., 30, 300-304.
97. Baell,J.B. and Huang,D.C.S. (2002) Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem. Pharmacol., 64, 851-863.
98. Kutzki,O., Park,H.S., Ernst,J.T., Orner,B.P., Yin,H. and Hamilton,A.D. (2002) Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J. Am. Chem. Soc., 124, 11838-11839.
99. Becattini,B., Kitada,S., Leone,M., Monosov,E., Chandler,S., Zhai,D., Kipps,T.J., Reed,J.C. and Pellecchia,M. (2004) Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting bcl-x(l). Chem. Biol., 11, 389-395.
100. Qian,J., Voorbach,M.J., Huth.J.R. et al. (2004) Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms. Anal. Biochem., 328, 131-138.
101. Schimmer,A.D., Welsh, K., Pinilla,C. et al. (2004) Small-molecule antagonists of apoptosis suppessor XIAP exhibit broad antitumor activity. Cancer 5, 25-35.
102. Franklin,M.C., Kadkhodayan,S., Ackerly,H. et al. (2003) Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry, 42, 8223-8231.
103. Arnt,C.R., Chiorean,M.V., Heldebrant,M.V., Gores,G.J. and Kaufmann,S.H. (2002) Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem., 277, 44236-44243.
104. Zhou,B.P. and Hung, M.C. (2003) Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin. Oncol., 30, 38-48.
105. Wakeling,A.E. (2002) Epidermal growth factor receptor tyrosine kinase inhibitors. Curr. Opin. Pharmacol., 2, 382-387.
106. Capdeville,R., Buchdunger,E., Zimmermann,J. and Matter,A. (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov., 1, 493-502.
107. Cartron,G., Watier,H., Golay,J. and Solal-Celigny,P. (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood, 104, 2635-2642.
108. Vasvilev,L.T., Vu,B.T., Graves,B. et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303, 844-848.